arrow
M

Marta Piqueras

consorci sanitari de terrassa
H指数:35
被引数:4,185

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcomes and Reclassification Patterns in Inflammatory Bowel Disease Unclassified: A Multicenter Study Matched With Ulcerative Colitis From Spanish ENEIDA Registry

炎症性肠病未分类患者的结局与再分类模式:一项与西班牙ENEIDA登记系统中溃疡性结肠炎患者匹配的多中心研究

2026-09-230
OAAI
Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU

炎症性储袋疾病的治疗:GETECCU的RESERVO研究中的见解与结果

2026-02-180
PRE
New insights into thiopurine toxicity: The contribution of rare XDH variants to myelotoxicity

硫嘌呤毒性的新见解:稀有XDH变异体对骨髓毒性的贡献

2025-08-130
PREAI
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA

生物制剂治疗炎症性肠病中剂量递增和递减的频率与效果:ENEIDA中的RAINBOW-IBD研究

2025-08-080
PRE
Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU
2025-02-011
PRE
Real-world short and long-term effectiveness of risankizumab in refractory Crohn's disease: RISANCROHN study from the ENEIDA Registry
2025-01-220
PRE
Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence

克罗恩病中的回肠优势与肠道手术增加和生物治疗使用增加相关,但治疗持续性较低。

2024-11-142
PRE
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry
2024-06-282
PRE
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project
2024-06-240
PRE
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
2024-05-080
OAAI
Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU
2024-03-042
OAAI
Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease
2024-03-010
PRE
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII)
2022-12-193
OAAI
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU
2022-12-148
PRE
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
2022-12-1410
PRE
Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
2022-07-052
OA
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
2022-02-015
OAAI
Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study)
2021-08-188
PREAI
Long-term outcomes of biologic therapy in Crohn's disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU
2021-05-270
PRE
Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU
2021-05-271
OA